{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:11:11Z","timestamp":1789603871214,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Aprepitant has been shown to reduce chemotherapy\u2010induced nausea and vomiting in children receiving highly emetogenic chemotherapy (HEC). In this study, we assessed the cost\u2010effectiveness of aprepitant for children receiving HEC in India, United Kingdom, and the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>We utilized individual patient\u2010level outcome data from a pediatric randomized trial, which demonstrated the superiority of an aprepitant\u2010based anti\u2010emetic prophylaxis over standard ondansetron and dexamethasone for HEC. Health state for each day of follow\u2010up was analyzed and quality\u2010adjusted life years (QALYs) were estimated. The incremental cost\u2010utility ratio (ICUR), incremental cost\u2010effectiveness ratio (ICER), and net monetary benefit (NMB) for each country were estimated. Sensitivity analyses by varying cost of aprepitant, hospitalization, and health state utility values by \u00b125% were conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Use of the aprepitant\u2010based regimen resulted in gain of 0.0019 QALY per chemotherapy cycle along with cost savings of $22.25, $1335.52, and $6612.10 for India, United Kingdom, and the United States, respectively. The cost savings per QALY was estimated to be $12,355.84 for India, $734,282.90 for the United Kingdom, and $3,567,564.11 for the United States. The cost savings for 50% gain in the percentage of days without grade 3 vomiting was $124.18 for India, $7451.63 for the United Kingdom, and $36,892.76 for the United States. The NMB for gain in QALY was $33.62, $1418.60, and $6727.01 for India, United Kingdom, and the United States, respectively. The estimates remained cost\u2010effective across all scenarios of the sensitivity analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Aprepitant\u2010based anti\u2010emetic regimen is cost\u2010effective for children receiving HEC. It results in overall cost savings and reduced healthcare\u2010resource utilization.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.29795","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T12:02:46Z","timestamp":1654171366000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost\u2010effectiveness analysis of aprepitant\u2010based anti\u2010emetic regimen for children receiving highly emetogenic chemotherapy: Individual patient data analysis of a randomized trial"],"prefix":"10.1002","volume":"69","author":[{"given":"Manraj Singh","family":"Sra","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-6088","authenticated-orcid":false,"given":"Shuvadeep","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Sasi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak Kumar","family":"Giri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azgar Abdul","family":"Rasheed","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-4407","authenticated-orcid":false,"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0173-z"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.31_suppl.155"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/23809000.2016.1174069"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare\u20102020\u2010002595"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00468-X"},{"issue":"3","key":"e_1_2_8_9_1","doi-asserted-by":"crossref","DOI":"10.1002\/cnr2.1149","article-title":"A qualitative study of the costs experienced by caregivers of children being treated for cancer in New Delhi, India","volume":"2","author":"Mardakis S","year":"2018","journal-title":"Cancer Rep (Hoboken)"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-010-0047-8"},{"issue":"3","key":"e_1_2_8_11_1","first-page":"171","article-title":"The impact of 5\u2010HT3RA use on cost and utilization in patients with chemotherapy\u2010induced nausea and vomiting: systematic review of the literature","volume":"7","author":"Broder MS","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001357"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26542"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2714-9"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70061-6"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21127"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.660514"},{"key":"e_1_2_8_18_1","volume-title":"IndiaMART \u2010 Indian Manufacturers Suppliers Exporters Directory, India Exporter Manufacturer"},{"key":"e_1_2_8_19_1","volume-title":"Online pharmacy India | buy medicines from India's trusted medicine store: 1mg.com. 1mg"},{"key":"e_1_2_8_20_1","volume-title":"BNF"},{"key":"e_1_2_8_21_1","volume-title":"NHS reference costs"},{"key":"e_1_2_8_22_1","volume-title":"National tariff payment system documents, annexes and supporting documents"},{"key":"e_1_2_8_23_1","volume-title":"Logistics O of P acquisition and pharmaceutical prices \u2010 Office of Procurement, Acquisition and Logistics (OPAL)"},{"key":"e_1_2_8_24_1","volume-title":"Prescription drug information, interactions & side effects"},{"key":"e_1_2_8_25_1","volume-title":"Medical supply store \u2010 USA Medical & Surgical Supplies"},{"key":"e_1_2_8_26_1","volume-title":"Price information"},{"key":"e_1_2_8_27_1","volume-title":"Healthcare Cost and Utilization Project (HCUP)"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.03.011"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0710-6"},{"key":"e_1_2_8_30_1","volume-title":"Making choices in health: WHO guide to cost\u2010effectiveness analysis","author":"World Health Organization","year":"2003"},{"key":"e_1_2_8_31_1","volume-title":"GDP per capita (current US$) \u2010 India | Data"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1481"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12170"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2012.03.002"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S44539"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00141.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0349-1"},{"issue":"2","key":"e_1_2_8_38_1","first-page":"89","article-title":"Cost\u2010consequence analysis of aprepitant compared to standard therapy (5\u2010HT3 + corticosteroids) for the prevention of highly emetogenic chemotherapy\u2010induced nausea and vomit [analisi di cost\u2010consequence di aprepitant rispetto alla terapia standard (5\u2010HT3 pi\u00f9 corticosteroidi) nella profilassi di un episodio di nausea e vomito indotto da chemioterapia altamente emetogena]","volume":"2","author":"Ravasio R","year":"2015","journal-title":"Glob Reg Health Technol Assess"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00871"},{"key":"e_1_2_8_40_1","article-title":"The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India","volume":"2016","author":"Babu G","year":"2016","journal-title":"Chemother Res Pract"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2015.002477"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29795","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29795","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T15:30:33Z","timestamp":1700667033000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/pbc.29795"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29795","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"2022-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29795"}}